

PERSONAL INFORMATION

Alberto Gajofatto

Date of birth 25/02/1978 | Nationality Italian | Social security number GJFLRT78B25L781V

📍 University of Verona, Department of Neuroscience, Biomedicine and Movement Sciences
Piazzale L.A. Scuro 10, 37134 Verona, Italy

☎ +39 045 8126778

✉ alberto.gajofatto@univr.it

🌐 <https://www.dnbm.univr.it/?ent=persona&id=6421#tab-presentazione>

PRESENT POSITION

Associate Professor in Neurology

Department of Neuroscience, Biomedicine and Movement Sciences
University of Verona, Italy

Consultant

Neurology Unit B – Azienda Ospedaliera Universitaria Integrata Verona

President of the Italian Association of Neuroepidemiology**Director of the PhD course of Neuroscience, Psychological and Psychiatric sciences, and Movement Sciences**

University of Verona, Italy

Coordinator of the Multiple Sclerosis Interdisciplinary Group**Director of the Regional Multiple Sclerosis Center**

Azienda Ospedaliera Universitaria Integrata Verona

Deputy Director of the Neurology Residency Program

University of Verona, Italy

WORK EXPERIENCE

from 2021

Associate Professor in Neurology

Department of Neuroscience, Biomedicine and Movement Sciences
University of Verona, Italy

from 2018 to 2021

Sr. Assistant Professor in Neurology

Department of Neuroscience, Biomedicine and Movement Sciences
University of Verona, Italy

from 2013 to 2018

Jr. Assistant Professor in Neurology

Department of Neuroscience, Biomedicine and Movement Sciences
University of Verona, Italy

November-December 2015

Visiting Researcher

Multiple Sclerosis Center, University of California, San Francisco, CA, USA

from 2012 to 2013

Research Fellow

Department of Neurological Sciences, University of Verona, Italy

from 2008 to 2012

Clinical Fellow

Policlinico G.B. Rossi, Neurology Department, Multiple Sclerosis Center, Verona, Italy

from 2006 to 2007

Post-Doctoral Fellow

Multiple Sclerosis Center, University of California, San Francisco, CA, USA

from 2003 to 2008 **Resident in Neurology**
Policlinico G.B. Rossi, Neurology Department, University of Verona, Italy

EDUCATION AND TRAINING

2025 **National Scientific Certification for the position of Full Professor in Neurology**

2017 **National Scientific Certification for the position of Associate Professor in Neurology**

Ph. D. Neuroscience

2012 University of Verona

2008 **Neurology Certification**
University of Verona

2003 **Medical Degree**
University of Verona

1997 **High School Diploma – scientific studies**
Liceo Scientifico A. Messedaglia, Verona

PERSONAL SKILLS

Mother tongue Italian

Other language(s)

	UNDERSTANDING		SPEAKING		WRITING
	Listening	Reading	Spoken interaction	Spoken production	
English	C1/2	C1/2	C1/2	C1/2	C1/2
	TOEIC Certificate (870/990)				
Spanish	A1/2	A1/2	A1/2	A1/2	A1/2

Organisational / managerial skills

President of the Italian Association of Neuroepidemiology; 2026 –
Member of the steering committee of the Italian Society of Neurology; 2026 –
Member of the territorial ethics committee of the southwestern Veneto area; 2023 –
Deputy Director of the Neurology Residency Program, University of Verona; 2022 –
Member of the Italian Association of Neuroepidemiology steering committee; 2014 –
Member of the PhD program in Neuroscience Board of Teachers, University of Verona; 2018 –
Member of the School of Medicine Board of Teachers, University of Verona; 2015 –
Member of the School of Nursing Board of Teachers, University of Verona; 2015 –
Member of the Neurology Residency Program Board of Teachers, University of Verona; 2014 –

CONCEPTION AND COORDINATION OF RESEARCH PROJECTS:

- One nerve, three views: multimodal testing of optic nerve involvement for multiple sclerosis diagnosis; 2025 – ongoing
- Assessment of sleep quality in adults with anti-MOG antibodies disease, NMOSD, and MS; 2024 – ongoing
- Longitudinal assessment of cognitive function, sleep, and patient reported outcomes in adults with anti-MOG antibodies disease, NMOSD, and MS; 2022 – ongoing;
- Longitudinal study of brain volume measures in adults with anti-MOG antibodies disease; 2019 – ongoing;

- Behaviour and well-being in young patients with multiple sclerosis – ESPRIMO project; 2018 – ongoing;
- Survival of multiple sclerosis patients in Verona, Italy; 2022-2024
- Body composition analysis and oxidative stress markers expression in young patients newly diagnosed with multiple sclerosis; 2018 – 2025
- Association of serum and CSF neurofilament light chain with outcome of multiple sclerosis, anti-MOG antibodies disease, neuromyelitis optica and other inflammatory conditions of the CNS; 2018 – 2025;
- Relevance of anti-aquaporin 4 and anti-MOG antibodies in the diagnosis of atypical demyelinating events of the central nervous system; 2016 – 2025;
- Association between candidate microRNAs expression in serum of patients with multiple sclerosis and the disease course; 2017 – 2025;
- Association of cerebrospinal fluid biomarkers with clinical and MRI measures of disease activity and progression in multiple sclerosis; 2014 – 2020;
- Validation study of 2010 McDonald criteria and 2016 MAGNIMS guidelines for the diagnosis of primary progressive multiple sclerosis; 2015 – 2017;
 - Brain functional MRI changes in multiple sclerosis patients with spasticity; 2014 – 2016
- Clinical and cognitive evolution of multiple sclerosis with benign course: a 5-year prospective study; 2013-2014
 - Natalizumab or fingolimod as second-line options for relapsing-remitting multiple sclerosis: an observational study; 2012 – 2014
 - Exploratory CSF biomarkers in patients with an initial demyelinating event of the CNS; 2009 – 2012
 - Predictors of recovery, symptom recurrence, conversion to multiple sclerosis and long-term disability after acute myelitis; 2007 – 2008
 - Impact of switching first-line disease-modifying therapy after treatment failure in relapsing-remitting multiple sclerosis; 2006 – 2007
- Prevalence of multiple sclerosis in Verona, Italy; 2004 – 2012

Job-related skills

- Clinical experience in general neurology
- Clinical experience in multiple sclerosis and related disorders
- Experience in clinical and translational research on multiple sclerosis and related disorders:
 - therapeutic strategies after first-line treatment
 - CSF and serum biomarkers with potential prognostic significance
 - epidemiology
- Participation to multicenter studies and clinical trials (list of projects from the last 3 years)
 - MultipleMS
 - ProgeMus
 - ConCure-SM
 - Matriosca
 - CladCross
 - Mnesys project, PNRR 2023
- participation to research groups
 - RireMS
 - Italian multiple sclerosis registry
 - Multiple sclerosis study group of the Italian Society of Neurology.

Computer skills

- good command of Microsoft Office™ tools
- good command of SPSS™

Teaching skills

University of Verona PhD School
Demyelinating diseases of the central nervous system

University of Verona School of Medicine:
Neurology (School of Nursing, Bolzano)
Neurology (School of Medicine)
Neurological examination and clinical reasoning in neurology (Neurology Residency Program)

Mentorship:
School of Medicine, University of Verona (Nursing Students, Medical Students, Residents)

Conferences and Meetings
organization and presentations

Organization:

- Verona Multiple Sclerosis Day; National CME conference (Verona); "Outcome measures of treatment" (Scientific supervisor); 15-11-2019
- 16th Congress of the Italian Association of Neuroepidemiology (digital edition); "COVID-19 pandemic and immigration: the role of neuroepidemiology" (steering committee); 24-09-2021
- 2nd Verona Multiple Sclerosis Day; International CME conference; "Toward a personalised therapy for multiple sclerosis: prognostic and predictive factors" (Scientific Supervisor); 16-12-2021
- 3rd Verona Multiple Sclerosis Day; National CME conference; Scientific supervisor; 23-06-2023
- 17th Congress of the Italian Association of Neuroepidemiology (steering committee); 9-11-2023, Alghero
- 4th Verona Multiple Sclerosis Day; National CME conference; Scientific supervisor; 16-05-2025
- 18th Congress of the Italian Association of Neuroepidemiology (steering committee); 21-11-2025

Presentations:

- 8th Congress of the European Federation of Neurological Societies (Paris): "Myelin oligodendrocyte glycoprotein and CD45 polymorphisms in multiple sclerosis: a case-control study" (poster); 04-09-2004 - 07-09-2004
- 129th Annual Meeting of the American Neurological Association (Toronto, CANADA): "Case-control study of myelin oligodendrocyte glycoprotein and CD45 polymorphisms in multiple sclerosis in Verona, Italy" (poster); 02-10-2004 - 06-10-2004
- 59th Annual Meeting of the American Academy of Neurology (Boston): "Switching disease-modifying therapy (DMT) after treatment failure: Does it have an impact on the course of relapsing-remitting multiple sclerosis (RRMS)?" (poster); 28-04-2007 - 05-05-2007
- 38th Congress of *Società Italiana di Neurologia* (Florence): "Demographic and clinical predictors of response to interferon-beta and glatiramer acetate as first-line treatment for relapsing-remitting multiple sclerosis" (platform); 13-10-2007 - 17-10-2007
- 38th Congress of *Società Italiana di Neurologia* (Florence): "Switching first-line disease-modifying therapy for relapsing-remitting multiple sclerosis in non-responders: is it a successful strategy?" (platform); 13-10-2007 - 17-10-2007
- 13th Congress of the Italian Association of Neuroepidemiology (Verona): "Early predictors of recovery, symptom recurrence, conversion to multiple sclerosis and long-term disability after acute myelitis" (poster); 26-09-2008 - 28-09-2008
- 134th Annual Meeting Annuale of the American Neurological Association (Baltimore, USA): "Increased cerebrospinal fluid cystatin C may predict disability after acute myelitis" (poster and platform); 11-10-2009 - 14-10-2009
- 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (Gotheborg): "Predicting the natural course of clinically isolated syndromes: an exploratory study of cerebrospinal fluid biomarkers"; 13-10-2010 - 16-10-2010
- 64th Annual Meeting of the American Academy of Neurology (New Orleans, USA): "A panel of exploratory CSF biomarkers in patients with an initial demyelinating event of the CNS: does it add relevant information to usual work-up?" (poster); 21-04-2012 - 28-04-2012
- 2nd International Congress on Neurology and Epidemiology (Nice): "Prevalence of multiple sclerosis in Verona, Italy: an epidemiologic and genetic study" (platform); 08-11-2012 - 10-11-2012
- 21st Annual Meeting of the European Charcot Foundation: "Clinical and biomarker assessment of initial demyelinating events suggestive of multiple sclerosis" (poster); "Prevalence of multiple sclerosis in Verona, Italy: an epidemiological and genetic study" (poster); 28-11-2013 - 30-11-2013
- HOT SPOT in MS: CME course (Verona): "Clinical efficacy of fingolimod" (platform); 13-06-2014
- 6th joint Meeting of the European Committee for Treatment and Research in Multiple Sclerosis and American Committee for Treatment and Research in Multiple Sclerosis (Boston): "Physical disability and cognitive impairment evolution in benign multiple sclerosis: a five-year prospective study" (poster); 10-09-2014 - 13-09-2014
- "Autoimmune encephalitides" CME course: "Role of CSF markers" (platform); 30-01-2015
- "Encephalomyelitides" National CME congress: "NMOSD diagnostic criteria" (platform); 19-02-2016
- "Multiple sclerosis: new perspectives" – National CME Congress (Verona); "Multiple Sclerosis: new classification of the clinical course" (platform); 15-04-2016
- 48th Congress of *Società Italiana di Neurologia* (Napoli): "Viral infections and autoimmune

- demyelinating diseases” (platform); 14-10-2017 - 17-10-2017
- 7th joint Meeting of the European Committee for Treatment and Research in Multiple Sclerosis and American Committee for Treatment and Research in Multiple Sclerosis (Paris): "Performance of 2010 McDonald criteria and 2016 MAGNIMS guidelines in the diagnosis of primary progressive multiple sclerosis" (poster); 25-10-2017 - 28-10-2017
- “Antibody-associated CNS disorders and their differential diagnosis” International CME conference (Verona): “Multiple Sclerosis and related disorders: When the diagnosis of MS is challenging” (platform); 22-02-2019
- 2nd Meeting of the Junior Academy of Multiple Sclerosis (Anacapri); JAMS Controversies: B lymphocytes – T lymphocytes (discussant); 25-05-2019
- 1st Verona Multiple Sclerosis Day (Verona); Treatment efficacy measures (congress chair); 15-11-2019
- 6th Congress of the European Academy of Neurology (Paris, virtual); “Neurofilament light chain level in paired CSF and serum samples of patients with multiple sclerosis: a prospective study” (platform); 23-05-2020
- 51st Congress of *Società Italiana di Neurologia* (Milano, virtual); “Formulation of research protocols: experimental studies” (platform); 29-11-2020
- “The silent progression of multiple sclerosis”; International CME conference (Riva del Garda) (discussant); 16-09-2021;
- 3rd Meeting of the Junior Academy of Multiple Sclerosis (Cagliari); Differential diagnosis: clinical cases – genetics (platform); 24-09-2021
- MS and beyond (Pollenzo); “Biomarkers” (platform); 19-05-2022
- A Digital Journey (Capri); “Il ruolo del digital communication manager nelle società scientifiche” (platform); 28-05-2022
- 4th Meeting of the Junior Academy of Multiple Sclerosis (Torino); “Inquinamento e sclerosi multipla” (platform); 24-09-2022
- Comportamenti e benessere – Progetto di Eccellenza 2018-2022 (Verona); “ESPRIMO: un intervento biopsicosociale cocreato con le persone con sclerosi multipla” (platform); 24-10-2022
- Konstellation – il futuro della SM tra ricerca, pratica clinica e nuove modalità di presa in carico del paziente (Venezia); “Ofatumumab: dalle evidenze scientifiche all’impatto sulla pratica clinica” (platform); 08-11-2022
- 8th Naples Meeting (Napoli); “Monoclonali non induttivi: iniettivi vs. sottocute” (platform); 25-11-2022
- MaveNews (webinar); “Breaking news fromECTRIMS: clinical study update – safety” (platform); 12-12-2022
- 9th course of Evidence Based Neurology (Ferrara); “EBM e Sclerosi Multipla” (platform); 16-12-2022
- RireMS meeting: Nuove frontiere nella valutazione e cura della sclerosi multipla progressiva (Roma); “Studio NMO-MOGAD” (platform); 17-02-2023
- 8th course of “Scuola Superiore di Neurologia – Società Italiana di Neurologia”; “Real world studies” (platform); 06-05-2023
- 6th Meeting of the Junior Academy of Multiple Sclerosis (Genova); “Promoting participatory research in chronicity” (platform); 03-10-2024
- 3rd Cuneo meeting of neuroimmunology; “MS news: soluble biomarkers” (platform); 07-03-2025
- Think Colors, BMS stand alone; “Il monitoraggio della progressione: focus sui nuovi biomarkers – biomarcatori fluidi”; Milano, 23-05-2025

Articles in Peer-Reviewed Journals

1. Gajofatto A, Bacchetti P, Grimes B, High A, Waubant E. Switching first-line disease-modifying therapy after failure: impact on the course of relapsing-remitting multiple sclerosis. *Mult Scler.* 2009; 15:50-58
2. Gajofatto A, Monaco S, Fiorini M, Zanusso G, Vedovello M, Rossi F, Turatti M, Benedetti MD. Assessment of outcome predictors in first-ever acute myelitis: a retrospective study on 53 cases. *Arch Neurol.* 2010; 67:724-730
3. Turatti M, Gajofatto A, Rossi F, Vedovello M, Benedetti MD. Long survival and clinical stability in Marburg's variant multiple sclerosis. *Neurol Sci.* 2010; 31:807-811
4. Castillo-Trivino T, Mowry EM, Gajofatto A, Chabas D, Crabtree-Hartman E, Cree B, Goodin DS, Green AJ, Okuda DT, Pelletier D, Zamvil SS, Vittinghoff E, Waubant E. Switching multiple sclerosis patients with breakthrough disease to second-line therapy. *Plos One* 2011; 6(2):e16664
5. Invernizzi P, Bertolasi L, Turatti M, Bianchi MR, Gajofatto A, Benedetti MD. Prognostic value of multimodal evoked potentials in multiple sclerosis: the EP score. *J Neurol.* 2011; 258:1933-1939
6. Zanusso G, Fiorini M, Ferrari S, Gajofatto A, Cagnin A, Galassi A, Richelli S, Monaco S. Cerebrospinal fluid markers in sporadic Creutzfeldt-Jakob disease. *Int J Mol Sci.* 2011;12(9):6281-92
7. Gajofatto A, Bongiani M, Zanusso G, Benedetti MD, Monaco S. Are cerebrospinal fluid biomarkers useful in predicting the prognosis of multiple sclerosis patients? *Int J Mol Sci* 2011; 12(11):7960-70
8. Bertolasi L, Adler M, Dall'ora E, Gajofatto A, Frasson E, Tocco P, Turri M, Ferlisi M, Fiorini M, Pimazzoni F, Squintani G, Martini M, Danzi B, Monaco S. Risk factors for post-polio syndrome among an Italian population: a case-control study. *Neurol Sci.* 2012; 33(6):1271-5
9. Monaco S, Ferrari S, Gajofatto A, Zanusso G, Mariotto S. HCV-Related Nervous System Disorders. *Clin Dev Immunol.* 2012; 2012:236148. Epub 2012 Jul 30
10. Gajofatto A, Benedetti MD. Prognostic factors of acute partial transverse myelitis. *Arch Neurol.* 2012; 69:1523
11. Turatti M, Gajofatto A, Bianchi MR, Ferrari S, Monaco S, Benedetti MD. Benign course of tumour-like multiple sclerosis: report of five cases and literature review. *J Neurol Sci.* 2013; 324(1-2):156-62
12. Gajofatto A, Stefani A, Turatti M, Bianchi MR, Gomez Lira M, Moretto G, Salviati A, Benedetti MD. Prevalence of multiple sclerosis in Verona, Italy: an epidemiologic and genetic study. *Eur J Neurol.* 2013; 20(4):697-703
13. Bertolasi L, Frasson E, Turri M, Gajofatto A, Bordignon M, Zanolin E, Martini M, Pimazzoni F, Ferlisi M, Zanusso G, Rossi M, Monaco S. A randomized controlled trial of IV immunoglobulin in patients with postpolio syndrome. *J Neurol Sci.* 2013; 330(1-2):94-99
14. Gajofatto A, Bongiani M, Zanusso G, Bianchi MR, Turatti M, Benedetti MD, Monaco S. Clinical and biomarker assessment of demyelinating events suggesting multiple sclerosis. *Acta Neurol Scand.* 2013; 128:336-344
15. Gajofatto A, Calabrese M, Benedetti MD, Monaco S. Clinical, MRI, and CSF markers of disability progression in multiple sclerosis. *Dis Markers* 2013;35(6):687-99
16. Gajofatto A, Bianchi MR, Deotto L, Benedetti MD. Are Natalizumab and Fingolimod analogous second-line options for the treatment of relapsing-remitting multiple sclerosis? A clinical practice observational study. *Eur Neurol.* 2014;72:173-180
17. Gajofatto A, Gobbin F, Piffer S, et al. Two Sisters with Leukoencephalopathy, Hearing Loss and Retinopathy: A Familial Case of Susac's Syndrome? *Journal of Advances in Medicine and Medical Research* 2014; 4:5818-5824 DOI: 10.9734/BJMMR/2014/12662
18. Calabrese M, Gajofatto A, Benedetti MD. Therapeutic strategies for relapsing-remitting multiple sclerosis: a special focus on reduction of grey matter damage as measured by brain atrophy. *Expert Rev Neurother.* 2014;14(12):1417-28.
19. Calabrese M, Gajofatto A, Gobbin F, Sala F, Turri G, Richelli S, Matinella A, Oliboni ES, Benedetti MD, Monaco S. Late-onset multiple sclerosis presenting with cognitive dysfunction and cortical/infratentorial atrophy. *Mult Scler.* 2015;21(5):580-89
20. Gandolfi M, Munari D, Geroi C, Gajofatto A, Benedetti MD, Midiri A, Carla F, Picelli A, Waldner A, Smania N. Sensory integration balance training in patients with multiple sclerosis: a randomized, controlled trial. *Mult Scler.* 2015 Oct;21(11):1453-62

21. Martinella A, Lanzafame M, Bonometti MA, Gajofatto A, Concia E, Vento S, Monaco S, Ferrari S. Neurological complications of HIV infection in pre-HAART and HAART era: a retrospective study. *J Neurol.* 2015;262(5):1317-27
22. Mattarozzi K, Casini F, Baldini M, Baldin E, Lugaresi A, Milani P, Pietrolongo E, Gajofatto A, Leone M, Riise T, Vignatelli L, D'Alessandro R, on behalf of G.E.Ro.N.I.Mu.S. group. Assessing subjective quality of life domains after multiple sclerosis diagnosis disclosure. *Health Expect.* 2016 Apr;19(2):437-47.
23. Gajofatto A, Turatti M, Bianchi MR, Forlivesi S, Gobbin F, Azzarà A, Monaco S, Benedetti MD. Benign multiple sclerosis: physical and cognitive impairment follow distinct evolutions. *Acta Neurol Scand.* 2016 Mar;133(3):183-91.
24. Gajofatto A, Benedetti MD. Treatment strategies for multiple sclerosis: when to start, when to change, when to stop? *World J Clin Cases* 2015 Jul 16;3(7):545-55
25. Calabrese M, Reynolds R, Magliozzi R, Castellaro M, Morra A, Scalfari A, Farina G, Romualdi C, Gajofatto A, Pitteri M, Benedetti MD, Monaco S. Regional Distribution and Evolution of Gray Matter Damage in Different Populations of Multiple Sclerosis Patients. *PLoS One.* 2015 Aug 12;10(8):e0135428
26. Mariotto S, Ferrari S, Sorio M, Benedetti F, Tridente G, Cavallaro T, Gajofatto A, Monaco S. Brentuximab vedotin: axonal microtubule's Apollyon. *Blood Cancer J.* 2015 Aug 28;5:e343
27. Monaco S, Mariotto S, Ferrari S, Calabrese M, Zanusso G, Gajofatto A, Sansonno D, Dammacco F. Hepatitis C virus-associated neurocognitive and neuropsychiatric disorders: Advances in 2015. *World J Gastroenterol.* 2015 Nov 14;21(42):11974-83
28. Gajofatto A, Turatti M, Monaco S, Benedetti MD. Clinical efficacy, safety, and tolerability of fingolimod for the treatment of relapsing-remitting multiple sclerosis. *Drug Healthc Patient Saf.* 2015 Dec 11;7:157-67
29. Patti F., Messina S., Amato M.P., Bergamaschi R., Bertolotto A., Bonavita S., Bruno Bossio R., Brescia Morra V., Costantino G.F., Cavalla P., Centonze D., Comi G., Cottone S., Danni M., Francia A., Gajofatto A., et al. A multicenter, observational study to evaluate the THC:CBD oromucosal spray (Sativex®) effects in la large population of Multiple Sclerosis patients: SA.FE. study, an Italian Experience. *J Neurol Neurosurg Psychiatry* 2016;87(9):944-51
30. Gajofatto A. Refractory trigeminal neuralgia responsive to nabiximols in a patient with multiple sclerosis. *Mult Scler Relat Disord.* 2016;8:64-5
31. Calabrese M, Castellaro M, Bertoldo A, De Luca A, Pizzini FB, Ricciardi GK, Pitteri M, Zimatore S, Magliozzi R, Benedetti MD, Manganotti P, Montemezzi S, Reynolds R, Gajofatto A, Monaco S. Epilepsy in multiple sclerosis: The role of temporal lobe damage. *Mult Scler.* 2017 Mar;23(3):473-482
32. Gajofatto A, Turatti M, Benedetti MD. Primary progressive multiple sclerosis: current therapeutic strategies and future perspectives. *Expert Rev Neurother.* 2017 Apr;17(4):393-406
33. Turri G, Calabrese M, Pancheri E, Monaco S, Gajofatto A, Marafioti V. QTc interval in patients with multiple sclerosis: an inference from the insula of Reil? *Eur J Neurol.* 2017 Mar;24(3):491-496
34. Farina G, Magliozzi R, Pitteri M, Reynolds R, Rossi S, Gajofatto A, Benedetti MD, Facchiano F, Monaco S, Calabrese M. Increased cortical lesion load and intrathecal inflammation is associated with oligoclonal bands in multiple sclerosis patients: a combined CSF and MRI study. *J Neuroinflammation.* 2017 Feb 21;14(1):40
35. Ferraro D, Franciotta D, Bedin R, Solaro C, Cocco E, Santangelo M, Immovilli P, Gajofatto A, Calabrese M, Di Filippo M, Orlandi R, Simone AM, Vitetta F, Capello E, Giunti D, Murialdo A, Frau J, Mariotto S, Gallina A, Gasperini C, Sola P; RIREMS group. A multicenter study on the diagnostic significance of a single cerebrospinal fluid IgG band. *J Neurol.* 2017 May;264(5):973-978
36. Messina S, Solaro C, Righini I, Bergamaschi R, Bonavita S, Bossio RB, Brescia Morra V, Costantino G, Cavalla P, Centonze D, Comi G, Cottone S, Danni MC, Francia A, Gajofatto A, et al. Sativex in resistant multiple sclerosis spasticity: Discontinuation study in a large population of Italian patients (SA.FE. study). *PLoS One.* 2017 Aug 1;12(8):e0180651
37. Gajofatto A, Nourbakhsh B, Benedetti MD, Waubant E. Performance of 2010 McDonald criteria and 2016 MAGNIMS guidelines in the diagnosis of primary progressive multiple sclerosis. *J Neurol Neurosurg Psychiatry.* 2017 Sep 22 [Epub ahead of print]
38. Gobbin F, Marangi A, Orlandi R, Richelli S, Turatti M, Calabrese M, Forgione A, Alessandrini F, Benedetti MD, Monaco S, Gajofatto A. A case of acute fulminant multiple sclerosis treated with alemtuzumab. *Mult Scler Relat Disord.* 2017 Oct;17:9-11
39. Mariotto S, Ferrari S, Monaco S, Benedetti MD, Schanda K, Alberti D, Farinazzo A, Capra R, Mancinelli C, De Rossi N, Bombardi R, Zuliani L, Zoccarato M, Tanel R, Bonora A, Turatti M, Calabrese M, Polo A, Pavone A, Grazian L, Sechi G, Sechi E, Urso D, Delogu R, Janes F, Deotto L, Cadaldini M, Bianchi MR, Cantalupo G, Reindl M, Gajofatto A. Clinical spectrum and IgG subclass analysis of anti-myelin oligodendrocyte glycoprotein antibody-associated syndromes: a multicenter study. *J Neurol.* 2017 Dec;264(12):2420-2430

40. Gajofatto A. Spotlight on siponimod and its potential in the treatment of secondary progressive multiple sclerosis: the evidence to date. *Drug Des Devel Ther.* 2017 Nov 2;11:3153-3157
41. Marangi A, Gajofatto A, Marastoni D, Gobbin F, Guiotto F, Tonin P, Benedetti MD. A case of multiple sclerosis and necrotizing autoimmune myopathy with anti-SRP antibodies. *Mult Scler Relat Disord.* 2017 Nov 23;19:118-120
42. Arru G, Sechi E, Mariotto S, Farinazzo A, Mancinelli C, Alberti D, Ferrari S, Gajofatto A, Capra R, Monaco S, Deiana GA, Caggiu E, Mamei G, Sechi LA, Pietro Sechi G. Antibody response against HERV-W env surface peptides differentiates multiple sclerosis and neuromyelitis optica spectrum disorder. *Mult Scler J Exp Transl Clin.* 2017 Nov 22;3(4):2055217317742425
43. Mariotto S, Farinazzo A, Monaco S, Gajofatto A, et al. Serum Neurofilament Light Chain in NMOSD and Related Disorders: Comparison According to Aquaporin-4 and Myelin Oligodendrocyte Glycoprotein Antibodies Status. *Mult Scler J Exp Transl Clin.* 2017 Nov 22;3(4):2055217317743098
44. Gajofatto A, Turatti M. Investigational immunosuppressants in early-stage clinical trials for the treatment of multiple sclerosis. *Expert Opin Investig Drugs.* 2018 Feb 23:1-14. doi: 10.1080/13543784.2018.1442437. [Epub ahead of print]
45. Bo M, Arru G, Sechi E, Niegowska M, Mariotto S, Mancinelli C, Farinazzo A, Alberti D, Gajofatto A, et al. Mycobacterium avium subspecies paratuberculosis and myelin basic protein specific epitopes are highly recognized by sera from patients with Neuromyelitis optica spectrum disorder. *J Neuroimmunol.* 2018;318:97-102
46. Magliozzi R, Howell OW, Nicholas R, Cruciani C, Castellaro M, Romualdi C, Rossi S, Pitteri M, Benedetti MD, Gajofatto A, Pizzini FB, Montemezzi S, Rasia S, Capra R, Bertoldo A, Facchiano F, Monaco S, Reynolds R, Calabrese M. Inflammatory intrathecal profiles and cortical damage in multiple sclerosis. *Ann Neurol.* 2018 Mar 8. doi: 10.1002/ana.25197. [Epub ahead of print]
47. Bacchin R, Macchione F, Cardellini D, Orlandi R, Gajofatto A, Zanusso G, Vattemi G. Levofloxacin-induced hemichorea-hemiballism in a patient with previous thalamic infarction. *Neurol Sci.* 2018 Mar 6. doi: 10.1007/s10072-018-3298-1. [Epub ahead of print]
48. Lanzillo R, Prosperini L, Gasperini C, Moccia M, Fantozzi R, Tortorella C, Nociti V, Annovazzi P, Cavalla P, Radaelli M, Malucchi S, Clerici VT, Boffa L, Buttari F, Ragonese P, Maniscalco GT, Di Filippo M, Buscarinu MC, Pinardi F, Gallo A, Coghe G, Pesci I, Laroni A, Gajofatto A, Calabrese M, Tomassini V, Cocco E, Solaro C; R.I.Re.MS study group. A multicentre observational analysis of PERSISTENCE to Treatment in the new multiple sclerosis era: the RESPECT study. *J Neurol.* 2018 Mar 16. doi: 10.1007/s00415-018-8831-x. [Epub ahead of print]
49. Benedetti MD, Marangi A, Bozzetti S, Gobbin F, Turatti M, Pea M, Gajofatto A, Mocella S. HPV-related papillary squamous cell carcinoma of the tonsil during treatment with fingolimod. *Mult Scler Relat Disord.* 2018 Jul;23:24-26. doi: 10.1016/j.msard.2018.04.018. Epub 2018 May 2.
50. Baldin E, Riise T, Mattarozzi K, Gajofatto A, Granella F, Leone M, Lugaresi A, Malagù S, Motti L, Neri W, Pesci I, Santangelo M, Scandellari C, Tola MR, Vignatelli L, Zenesini C, D'Alessandro R; G.E.Ro.N.I.Mu.S. study group. Health-related quality of life in clinically isolated syndrome and risk of conversion to multiple sclerosis. *Neurol Sci.* 2018 Sep 25. doi: 10.1007/s10072-018-3582-0. [Epub ahead of print]
51. Gandolfi M, Valè N, Dimitrova EK, Mazzoleni S, Battini E, Benedetti MD, Gajofatto A, Ferraro F, Castelli M, Camin M, Filippetti M, De Paoli C, Chemello E, Picelli A, Corradi J, Waldner A, Saltuari L, Smania N. Effects of High-intensity Robot-assisted Hand Training on Upper Limb Recovery and Muscle Activity in Individuals With Multiple Sclerosis: A Randomized, Controlled, Single-Blinded Trial. *Front Neurol.* 2018 Oct 24;9:905. doi: 10.3389/fneur.2018.00905. eCollection 2018.
52. Gobbin F, Zaroni M, Marangi A, Orlandi R, Crestani L, Benedetti MD, Gajofatto A. 2017 McDonald criteria for multiple sclerosis: Earlier diagnosis with reduced specificity? *Mult Scler Relat Disord.* 2019 Apr;29:23-25.
53. Mariotto S, Gajofatto A, Zuliani L, Zoccarato M, Gastaldi M, Franciotta D, Cantalupo G, Piardi F, Polo A, Alberti D, Sartori S, Zanusso G, Agrò L, Demurtas R, Sechi G, Sechi E, Monaco S, Ferrari S. Serum and CSF neurofilament light chain levels in antibody-mediated encephalitis. *J Neurol.* 2019 Jul;266(7):1643-1648. doi: 10.1007/s00415-019-09306-z. Epub 2019 Apr 3.
54. Mariotto S, Ferrari S, Gastaldi M, Franciotta D, Sechi E, Capra R, Mancinelli C, Schanda K, Alberti D, Orlandi R, Bombardi R, Zuliani L, Zoccarato M, Benedetti MD, Tanel R, Calabria F, Rossi F, Pavone A, Grazian L, Sechi G, Batzu L, Murdeu N, Janes F, Fetoni V, Fulitano D, Stenta G, Federle L, Cantalupo G, Reindl M, Monaco S, Gajofatto A. Neurofilament light chain serum levels reflect disease severity in MOG-Ab associated disorders. *J Neurol Neurosurg Psychiatry.* 2019 Nov;90(11):1293-1296. doi: 10.1136/jnnp-2018-320287. Epub 2019 Apr 5.
55. Calabrese M, Gasperini C, Tortorella C, Schiavi G, Frisullo G, Ragonese P, Fantozzi R, Prosperini L,

- Annovazzi P, Cordioli C, Di Filippo M, Ferraro D, Gajofatto A, Malucchi S, Lo Fermo S, De Luca G, Stromillo ML, Cocco E, Gallo A, Paolicelli D, Lanzillo R, Tomassini V, Pesci I, Rodegher ME, Solaro C; RIREMS group (Rising Italian Researchers in Multiple Sclerosis). "Better explanations" in multiple sclerosis diagnostic workup: A 3-year longitudinal study. *Neurology*. 2019 May 28;92(22):e2527-e2537. doi: 0.1212/WNL.0000000000007573.
56. Hofer LS, Mariotto S, Wurth S, Ferrari S, Mancinelli CR, Delogu R, Monaco S, Gajofatto A, Schwaiger C, Rostasy K, Deisenhammer F, Höftberger R, Berger T, Reindl M. Distinct serum and cerebrospinal fluid cytokine and chemokine profiles in autoantibody-associated demyelinating diseases. *Mult Scler J Exp Transl Clin*. 2019 May 15;5(2):2055217319848463. doi: 10.1177/2055217319848463. eCollection 2019 Apr-Jun.
57. Gajofatto A, Donisi V, Busch IM, Gobbin F, Butturini E, Calabrese M, Carcereri de Prati A, Cesari P, Del Piccolo L, Donadelli M, Fabene P, Fochi S, Gomez-Lira M, Magliozzi R, Malerba G, Mariotti R, Mariotto S, Milanese C, Romanelli MG, Sbarbati A, Schena F, Mazzi MA, Rimondini M. Biopsychosocial model of resilience in young adults with multiple sclerosis (BPS-ARMS): an observational study protocol exploring psychological reactions early after diagnosis. *BMJ Open*. 2019 Aug 2;9(8):e030469. doi: 10.1136/bmjopen-2019-030469.
58. Solari A, Giovannetti AM, Giordano A, Tortorella C, Torri Clerici V, Bricchetto G, Granella F, Lugaresi A, Patti F, Salvetti M, Pesci I, Pucci E, Centonze D, Danni MC, Bonavita S, Ferraro D, Gallo A, Gajofatto A, Nociti V, Grimaldi L, Grobberio M, Lanzillo R, Di Giovanni R, Gregori S, Manni A, Pietrolongo E, Bertagnoli S, Ronzoni M, Compagnucci L, Fantozzi R, Allegri B, Arena S, Buscarinu MC, Sabattini L, Quartuccio ME, Tsantes E, Confaloneri P, Tacchino A, Schiffmann I, Rahn AC, Kleiter I, Messmer Uccelli M, Barabasch A, Heesen C, The ManTra Project. Conversion to Secondary Progressive Multiple Sclerosis: Patient Awareness and Needs. Results From an Online Survey in Italy and Germany. *Front Neurol*. 2019 Aug 22;10:916. doi: 10.3389/fneur.2019.00916. eCollection 2019.
59. Magliozzi R, Marastoni D, Rossi S, Castellaro M, Mazziotti V, Pitteri M, Gajofatto A, Monaco S, Benedetti MD, Calabrese M. Increase of CSF inflammatory profile in a case of highly active multiple sclerosis. *BMC Neurol*. 2019 Sep 26;19(1):231. doi: 10.1186/s12883-019-1455-7.
60. Ferraro D, Annovazzi P, Moccia M, Lanzillo R, De Luca G, Nociti V, Fantozzi R, Paolicelli D, Ragonese P, Gajofatto A, Boffa L, Cavalla P, Lo Fermo S, Buscarinu MC, Loreface L, Cordioli C, Calabrese M, Gallo A, Pinardi F, Tortorella C, Di Filippo M, Camera V, Maniscalco GT, Radaelli M, Buttari F, Tomassini V, Cocco E, Gasperini C, Solaro C; RIREMS (Rising Researchers in Multiple Sclerosis). Characteristics and treatment of Multiple Sclerosis-related trigeminal neuralgia: An Italian multi-centre study. *Mult Scler Relat Disord*. 2020 Jan;37:101461. doi: 10.1016/j.msard.2019.101461. Epub 2019 Oct 19.
61. Mariotto S, Gajofatto A, Batzu L, Delogu R, Sechi G, Leoni S, Pirastru MI, Bonetti B, Zanoni M, Alberti D, Schanda K, Monaco S, Reindl M, Ferrari S. Relevance of antibodies to myelin oligodendrocyte glycoprotein in CSF of seronegative cases. *Neurology*. 2019 Nov 12;93(20):e1867-e1872.
62. Arru G, Sechi E, Mariotto S, Zarbo IR, Ferrari S, Gajofatto A, Monaco S, Deiana GA, Bo M, Sechi LA, Sechi GP. Antibody response against HERV-W in patients with MOG-IgG associated disorders, multiple sclerosis and NMOSD. *J Neuroimmunol*. 2020 Jan 15;338:577110. doi: 10.1016/j.jneuroim.2019.577110. Epub 2019 Nov 6.
63. Gajofatto A, Turatti M. Siponimod to treat secondary progressive multiple sclerosis. *Drugs Today (Barc)*. 2020 Jan;56(1):37-46. doi: 10.1358/dot.2020.56.1.3091905.
64. Marangi A, Farina G, Vicenzi V, Forlivesi S, Calabria F, Marchioretto F, Forgione A, Rossi F, Stenta G, Vianello M, Gajofatto A, Benedetti MD. Changing therapeutic strategies and persistence to disease-modifying treatments in a population of multiple sclerosis patients from Veneto region, Italy. *Mult Scler Relat Disord*. 2020 Jun;41:102004. doi: 10.1016/j.msard.2020.102004. Epub 2020 Feb 10.
65. Valè N, Gandolfi M, Mazzoleni S, Battini E, Dimitrova EK, Gajofatto A, Ferraro F, Castelli M, Camin M, Filippetti M, De Paoli C, Picelli A, Corradi J, Chemello E, Waldner A, Saltuari L, Smania N. Characterization of Upper Limb Impairments at Body Function, Activity, and Participation in Persons With Multiple Sclerosis by Behavioral and EMG Assessment: A Cross-Sectional Study. *Front Neurol*. 2020 Feb 14;10:1395. doi: 10.3389/fneur.2019.01395. eCollection 2019.
66. Mantovani LG, Cozzolino P, Cortesi PA, Patti F; SA.FE. study group. Cost-Effectiveness Analysis of Cannabinoid Oromucosal Spray Use for the Management of Spasticity in Subjects with Multiple Sclerosis. *Clin Drug Investig*. 2020 Apr;40(4):319-326. doi: 10.1007/s40261-020-00895-6.
67. Tortorella C, Solaro C, Annovazzi P, Boffa L, Buscarinu MC, Buttari F, Calabrese M, Cavalla P, Cocco E, Cordioli C, De Luca G, Di Filippo M, Fantozzi R, Ferraro D, Gajofatto A, Gallo A, Lanzillo R, Laroni A, Fermo SL, Malucchi S, Maniscalco GT, Moccia M, Nociti V, Paolicelli D, Pesci I, Prosperini L, Ragonese P, Tomassini V, Clerici VLAT, Rodegher M, Gherardi M, Gasperini C, RIReMS Group. Informing MS patients on treatment options: a consensus on the process of consent taking. *Neurol Sci*. 2020 Aug;41(8):2249-2253
68. Tonin P, Pancheri E, Orlandi R, Gajofatto A, Rinaldi R, D'Angelo R, Papa V, Vattemi G, Cenacchi G. Amyloid myopathy: an intriguing diagnosis. *Clin Neurol Neurosurg*. 2020 Aug;195:105848
69. Orlandi R, Mariotto S, Ferrari S, Gobbin F, Sechi E, Capra R, Mancinelli CR, Bombardi R, Zuliani L,

- Zoccarato M, Rossi F, Camera V, Ferraro D, Benedetti MD, Reindl M, Gajofatto A. Diagnostic features of initial demyelinating events associated with serum MOG-IgG. *J Neuroimmunol*. 2020 Jul 15;344:577260.
70. Zanoni M, Orlandi E, Rossetti G, Turatti M, Calabrese M, Gomez Lira M, Gajofatto A. Upregulated serum miR-128-3p in progressive and relapse-free multiple sclerosis patients. *Acta Neurol Scand*. 2020 Nov;142(5):511-516.
71. D'Amico E, Zanghi A, Sciandra M, Lanzillo R, Callari G, Cortese A, Lus G, Lucchini M, Buccafusca M, Bonavita S, Gallo A, Curti E, Gajofatto A, Signoriello E, Bisecco A, Gobbin F, Ferrò MT, Ferrazzano G, Sparaco M, Valentino P, Mirabella M, Granella F, Bresciamorra V, Grimaldi LME, Patti F; ITALIAN-DIME-TERI group. Dimethyl fumarate vs Teriflunomide: an Italian time-to-event data analysis. *J Neurol*. 2020 Oct;267(10):3008-3020
72. Moccia M, Annovazzi P, Buscarinu MC, Calabrese M, Cavalla P, Cordioli C, Di Filippo M, Ferraro D, Gajofatto A, Gallo A, Lanzillo R, Laroni A, Loreface L, Mallucchi S, Nociti V, Paolicelli D, Pinardi F, Prosperini L, Radaelli M, Ragonese P, Tomassini V, Tortorella C, Cocco E, Gasperini C, Solaro C. Harmonization of real-world studies in multiple sclerosis: Retrospective analysis from the rirms group. *Mult Scler Relat Disord*. 2020 Oct;45:102394.
73. Chisari CG, Solaro C, Annunziata P, Bergamaschi R, Bianco A, Bonavita S, Brescia Morra V, Bruno Bossio R, Capello E, Castelli L, Cavalla P, Costantino G, Centonze D, Cottone S, Danni MC, Esposito F, Gajofatto A, Gasperini C, Guareschi A, Lanzillo R, Lus G, Maniscalco GT, Matta M, Paolicelli D, Petrucci L, Pontecorvo S, Righini I, Rovaris M, Sessa E, Spinicci G, Spitaleri D, Valentino P, Zaffaroni M, Zappia M, Patti F. Nabiximols discontinuation rate in a large population of patients with multiple sclerosis: a 18-month multicentre study. *J Neurol Neurosurg Psychiatry*. 2020 Sep;91(9):914-920
74. Lepore V, Bosetti C, Santucci C, Iaffaldano P, Trojano M, Mosconi P; Italian Multiple Sclerosis Register Centers Group. Detection of disability worsening in relapsing-remitting multiple sclerosis patients: a real-world roving Expanded Disability Status Scale reference analysis from the Italian Multiple Sclerosis Register. *Eur J Neurol*. 2021 Feb;28(2):567-578
75. Di Gregorio M, Torri Clerici VLA, Fenu G, Gaetani L, Gallo A, Cavalla P, Ragonese P, Annovazzi P, Gajofatto A, Prosperini L, Landi D, Nicoletti CG, Di Carmine C, Totaro R, Nociti V, De Fino C, Ferraro D, Tomassini V, Tortorella C, Righini I, Amato MP, Manni A, Paolicelli D, Iaffaldano P, Lanzillo R, Moccia M, Buttari F, Fantozzi R, Cerqua R, Zagaglia S, Farina D, De Luca G, Buscarinu MC, Pinardi F, Cocco E, Gasperini C, Solaro CM, Di Filippo M. Defining the course of tumefactive multiple sclerosis: A large retrospective multicentre study. *Eur J Neurol*. 2021 Apr;28(4):1299-1307
76. Mariotto S, Gastaldi M, Grazian L, Mancinelli C, Capra R, Marignier R, Alberti D, Zanzoni S, Schanda K, Franciotta D, Calabria F, Monaco S, Reindl M, Ferrari S, Gajofatto A. NFL levels predominantly increase at disease onset in MOG-Abs-associated disorders. *Mult Scler Relat Disord*. 2021 Feb 11;50:102833
77. Donisi V, Gajofatto A, Mazzi MA, Gobbin F, Busch IM, Ghellere A, Rimondini M. Insights for Fostering Resilience in Young Adults With Multiple Sclerosis in the Aftermath of the COVID-19 Emergency: An Italian Survey. *Front Psychiatry*. 2021 Feb 22;11:588275
78. Donisi V, Gajofatto A, Mazzi MA, Gobbin F, Busch IM, Ghellere A, Klonova A, Rudi D, Vitali F, Schena F, Del Piccolo L, Rimondini M. A Bio-Psycho-Social Co-created Intervention for Young Adults With Multiple Sclerosis (ESPRIMO): Rationale and Study Protocol for a Feasibility Study. *Front Psychol*. 2021 Feb 23;12:598726
79. Ferraro D, Annovazzi P, Lanzillo R, Calabrese M, Fantozzi R, De Luca G, Cordioli C, Paolicelli D, Ragonese P, Gajofatto A, Lo Fermo S, Cavalla P, Tortorella C, Pesci I, Gallo A, Pinardi F, Di Filippo M, Maniscalco GT, Nociti V, Radaelli M, Tomassini V, Buscarinu MC, Moccia M, Camera V, Cocco E, Gasperini C, Solaro C. A multicenter survey on access to care in Multiple Sclerosis-related trigeminal neuralgia. *J Neurol Sci*. 2021 Mar 27;424:117430.
80. Poli S, Rimondini M, Gajofatto A, et al. "If You Can't Control the Wind, Adjust Your Sail": Tips for Post-Pandemic Benefit Finding from Young Adults Living with Multiple Sclerosis. A Qualitative Study. *Environ Res Public Health*. 2021 Apr 14;18(8):4156
81. Zuccalà M, Barizzone N, Boggio E, Gigliotti L, Sorosina M, Basagni C, Bordoni R, Clarelli F, Anand S, Mangano E, Vecchio D, Corsetti E, Martire S, Perga S, Ferrante D, Gajofatto A, et al. Genomic and functional evaluation of TNFSF14 in multiple sclerosis susceptibility. *J Genet Genomics*. 2021 Jun 20;48(6):497-507.
82. De Panfilis L, Veronese S, Bruzzone M, Cascioli M, Gajofatto A, et al. Study protocol on advance care planning in multiple sclerosis (ConCure-SM): intervention construction and multicentre feasibility trial. *BMJ Open*. 2021 Aug 13;11(8):e052012.
83. Di Filippo M, Cordioli C, Malucchi S, Annovazzi P, Cavalla P, Torri Clerici V, Ragonese P, Nociti V, Radaelli M, Laroni A, Buttari F, Loreface L, Ferraro D, Gajofatto A, et al. mRNA COVID-19 vaccines do not increase the short-term risk of clinical relapses in multiple sclerosis. *J Neurol Neurosurg Psychiatry*. 2021 Aug 18;jnnp-2021-327200.

84. Gajofatto A, Orlandi R. Ofatumumab for relapsing forms of multiple sclerosis. *Drugs Today* 2022 Jan;58(1):9-21.
85. Buonomo AR, Viceconte G, Calabrese M, De Luca G, Tomassini V, Cavalla P, Maniscalco GT, Ferraro D, Nociti V, Radaelli M, Buscarinu MC, Paolicelli D, Gajofatto A, et al. Management of hepatitis B virus prophylaxis in patients treated with disease-modifying therapies for multiple sclerosis: a multicentric Italian retrospective study. *J Neurol*. 2022 Jun;269(6):3301-3307.
86. Dinoto A, Sechi E, Ferrari S, Gajofatto A, et al. Risk of disease relapse following COVID-19 vaccination in patients with AQP4-IgG-positive NMOSD and MOGAD. *Mult Scler Relat Disord*. 2022 Feb;58:103424.
87. Bergamaschi R, Beghi E, Bosetti C, et al. Do patients' and referral centers' characteristics influence multiple sclerosis phenotypes? Results from the Italian multiple sclerosis and related disorders register. *Neurol Sci*. 2022 Sep;43(9):5459-5469.
88. Orlandi R, Mariotto S, Gajofatto A. Prevalence, incidence, and season distribution of MOG antibody-associated disease in the province of Verona, Italy. *Mult Scler Relat Disord*. 2022 Jul;63:103884.
89. Donisi V, Poli S, Mazzi MA, Gobbin F, Schena F, Del Piccolo L, Bigardi V, Gajofatto A, Rimondini M. Promoting participatory research in chronicity: The ESPRIMO biopsychosocial intervention for young adults with multiple sclerosis. *Front Psychol*. 2022 Nov 3;13:1042234.
90. Carta S, Cobo Calvo Á, Armangué T, et al. Significance of Myelin Oligodendrocyte Glycoprotein Antibodies in CSF: A Retrospective Multicenter Study. *Neurology*. 2023 Mar 14;100(11):e1095-e1108.
91. Gajofatto A, Cardobi N, Gobbin F, Calabrese M, Turatti M, Benedetti MD. Resting-state functional connectivity in multiple sclerosis patients receiving nabiximols for spasticity. *BMC Neurol*. 2023 Mar 29;23(1):128.
92. Capuano R, et al. Symptomatic COVID-19 course and outcomes after three mRNA vaccine doses in multiple sclerosis patients treated with high-efficacy DMTs. *Mult Scler*. 2023 Jun;29(7):856-865. doi: 10.1177/13524585231167515.
93. Altieri M, Capuano R, Bisecco A, d'Ambrosio A, Risi M, Cavalla P, Vercellino M, Annovazzi P, Zaffaroni M, De Stefano N, Stromillo ML, D'Amico E, Zanghi A, Buscarinu MC, Lanzillo R, De Luca G, Calabrese M, Lorefice L, Di Filippo M, Valentino P, Gajofatto A, et al. Quality of care provided by Multiple Sclerosis Centers during Covid-19 pandemic: Results of an Italian multicenter patient-centered survey. *Mult Scler Relat Disord*. 2023 Sep;77:104870. doi: 10.1016/j.msard.2023.104870. Epub 2023 Jul 14.
94. Di Filippo M, Ferraro D, Ragonese P, Prosperini L, Maniscalco GT, Gallo A, Cavalla P, Lorefice L, Nociti V, Di Sabatino E, Clerico M, Guaschino C, Radaelli M, Fantozzi R, Buttari F, Laroni A, Gajofatto A, et al. SARS-CoV-2 vaccination and multiple sclerosis: a large multicentric study on relapse risk after the third booster dose. *J Neurol*. 2024 Jan;271(1):24-31. doi: 10.1007/s00415-023-12034-0. Epub 2023 Nov 3.
95. Bianchi A, Matranga D, Patti F, Maniscalco L, Pilotto S, Di Filippo M, Zaffaroni M, Annovazzi P, Bertolotto A, Gasperini C, Quartuccio E, Centonze D, Fantozzi R, Gajofatto A, et al. The role of ethnicity and native-country income in multiple sclerosis: the Italian multicentre study (MS-MigIT). *J Neurol*. 2024 May;271(5):2182-2194. doi: 10.1007/s00415-024-12214-6. Epub 2024 Feb 16.
96. Poli S, Donisi V, Mazzi MA, Gobbin F, Giusto G, Orlandi R, Schena F, Del Piccolo L, das Nair R, Gajofatto A, Rimondini M. Fostering quality of life in young adults living with multiple sclerosis: a pilot study of a co-created integrated intervention. *Front Psychol*. 2024 Mar 26;15:1342166. doi: 10.3389/fpsyg.2024.1342166. eCollection 2024.
97. Nociti V, Romozzi M, Prosperini L, Clerici VT, Ragonese P, Gallo A, Maniscalco GT, Di Filippo M, Buscarinu MC, Lorefice L, Pinardi F, Gajofatto A, Cavalla P, Buttari F, Ferraro D, De Luca G, Solaro C, Gasperini C, Cocco E; RIREMS Study Group. Effect of autoimmune comorbidities on multiple sclerosis course: An observational multicenter study. *Eur J Neurol*. 2025 Jan;32(1):e70019. doi: 10.1111/ene.70019.
98. Gajofatto A, Rimondini M. We need to engage representative patients' community rather than "expert patients" to increase impact of research in the era of personalized medicine: No. *Mult Scler*. 2025 Apr;31(4):393-395. doi: 10.1177/13524585251315354.
99. Orlandi R, Mariotto S, Gobbin F, Rossi F, Camera V, Calabrese M, Calabria F, Gajofatto A. Brain Volume Measures in Adults with MOG-Antibody-Associated Disease: A Longitudinal Multicenter Study. *J Clin Med*. 2025 Apr 3;14(7):2445. doi: 10.3390/jcm14072445.
100. Orlandi R, Bonomi F, Calabria F, Gajofatto A. Life and Death with Multiple Sclerosis: 20 Years Reappraisal of Verona Prevalence Cohort. *Neuroepidemiology*. 2025 Apr 24:1-12. doi: 10.1159/000544845.
101. Carta S, Sechi E, Dinoto A, Mancinelli C, Greco G, Maniscalco GT, Comacchini S, Giannoccaro MP, Calabria F, Marziali A, Masciocchi S, Risi M, Cossu A, Volonghi I, Cantalupo G, Zoccarato M, Orlandi R, Del Zotto E, Ferraro D, Trentinaglia M, De Biase S, Grazian L, Caleri F, Bianchi MR, Rossi P, Virgilio E, Capobianco

- M, Cortese R, Tortorella C, Rossi F, De Luca G, Perelli A, Bozzetti S, Zuliani L, Nosadini M, Sartori S, Brambilla L, Gajofatto A, Vogrig A, Massacesi L, Damato V, Gastaldi M, Mariotto S. Real-Life Evaluation of the MOGAD Diagnostic Criteria: Application Challenges and Discrepancies. *Neurol Neuroimmunol Neuroinflamm*. 2025 Sep;12(5):e200456. doi: 10.1212/NXI.000000000200456.
102. Orlandi R, Torresan L, Gobbin F, Orlandi E, Gomez Lira M, Gajofatto A. Serum Levels of miR-34a-5p, miR-30b-5p, and miR-140-5p Are Associated with Disease Activity and Brain Atrophy in Early Multiple Sclerosis. *Int J Mol Sci*. 2025 Sep 4;26(17):8597. doi: 10.3390/ijms26178597.
103. Poli S, Donisi V, das Nair R, Mazzi MA, Gajofatto A, Rimondini M. Psychosocial Correlates of Fatigue in Young Adults with Multiple Sclerosis: Exploring the Roles of Resilience, Mindfulness, and Illness Perception. *Healthcare (Basel)*. 2025 Sep 17;13(18):2335. doi: 10.3390/healthcare13182335.
104. Solari A, De Panfilis L, Zagarella RM, Ghirotto L, Farinotti M, Gajofatto A, Grasso MG, Kruger P, Lugaresi A, Mattarozzi K, Montepietra S, Patti F, Pucci E, Rimondini M, Solaro C, Perin M, Giordano A, Veronese S; ConCure-SM project. Advance care planning in multiple sclerosis (ConCure-SM): A multicenter single-arm pilot and feasibility study. *PLoS One*. 2025 Oct 7;20(10):e0331220. doi: 10.1371/journal.pone.0331220.
105. Portaccio E, et al on behalf of Italian Multiple Sclerosis and Related Disorders Register. Toward a Unified Definition of Progression Independent of Relapse Activity in Multiple Sclerosis. *Neurology*. 2025 Oct 21;105(8):e213977.
106. Bartiromo S, Alves C, O'Mahony J, Yeh EA, Marrie RA, Narayanan S, Waters PJ, Gajofatto A, Bar-Or A, Banwell BL, Fadda G; Canadian Pediatric Demyelinating Disease Network. Spinal Cord Leptomeningeal Enhancement as a Marker of Extensive Spinal Cord Involvement in Children With MOGAD. *Neurol Neuroimmunol Neuroinflamm*. 2026 Jan;13(1):e200449.
107. Carta S, Tiberi R, De Rossi N, et al. Validation of the MOG-AR Score: A Retrospective Multicenter Study. *Neurol Neuroimmunol Neuroinflamm*. 2026 Mar;13(2):e200547.
108. Gandolfi M, Crestani M, Perachiotti G, Salaorni F, Baroni A, Gajofatto A, et al. The effectiveness of combining a home-based Digital motor Telerehabilitation program with conventional therapy in progressive multiple sclerosis: A study protocol for a multicenter, randomized controlled trial. *Digit Health*. 2025 Jul 23;11:20552076251323995. doi: 10.1177/20552076251323995.

<https://www.ncbi.nlm.nih.gov/pubmed/?term=gajofatto+a>

Awards

- Young Investigator Award for Multiple Sclerosis Research 2013; European Charcot Foundation 21st Annual Meeting; Baveno, Italy, 28-30 November 2013
- Neuroimmunology and Demyelinating Diseases Special Interest Group; American Neurological Association 134th Annual Meeting; Baltimore, MD, October 2009

Citation Overview

Total cited documents: 114
 Total number of citations: 2821
 H-Index: 28
 Source: *Scopus*, accessed on February 12th, 2026

Verona, March 2nd, 2026

